- Home
- ELVN vs VMEO Comparison
ELVN vs VMEO Comparison
Compare ELVN & VMEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- VMEO
- Stock Information
- Founded
- ELVN 2016
- VMEO 2004
- Country
- ELVN United States
- VMEO United States
- Employees
- ELVN N/A
- VMEO N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- VMEO Computer Software: Prepackaged Software
- Sector
- ELVN Health Care
- VMEO Technology
- Exchange
- ELVN Nasdaq
- VMEO Nasdaq
- Market Cap
- ELVN 1.1B
- VMEO 1.0B
- IPO Year
- ELVN 2020
- VMEO N/A
- Fundamental
- Price
- ELVN $21.86
- VMEO $6.52
- Analyst Decision
- ELVN Strong Buy
- VMEO Buy
- Analyst Count
- ELVN 5
- VMEO 3
- Target Price
- ELVN $37.80
- VMEO $8.67
- AVG Volume (30 Days)
- ELVN 220.2K
- VMEO 1.3M
- Earning Date
- ELVN 03-13-2025
- VMEO 02-19-2025
- Dividend Yield
- ELVN N/A
- VMEO N/A
- EPS Growth
- ELVN N/A
- VMEO 290.90
- EPS
- ELVN N/A
- VMEO 0.20
- Revenue
- ELVN N/A
- VMEO $419,394,000.00
- Revenue This Year
- ELVN N/A
- VMEO $1.32
- Revenue Next Year
- ELVN N/A
- VMEO $2.07
- P/E Ratio
- ELVN N/A
- VMEO $32.99
- Revenue Growth
- ELVN N/A
- VMEO 0.52
- 52 Week Low
- ELVN $10.90
- VMEO $3.43
- 52 Week High
- ELVN $30.03
- VMEO $7.90
- Technical
- Relative Strength Index (RSI)
- ELVN 44.27
- VMEO 51.98
- Support Level
- ELVN $21.45
- VMEO $6.11
- Resistance Level
- ELVN $22.82
- VMEO $6.44
- Average True Range (ATR)
- ELVN 1.55
- VMEO 0.25
- MACD
- ELVN 0.00
- VMEO 0.00
- Stochastic Oscillator
- ELVN 32.63
- VMEO 58.65
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. Its comprehensive and cloud-based tools empower its users to create, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.